United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - bromocriptine mesilate - oral suspension - 4mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - bromocriptine mesilate - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - bromocriptine mesilate - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

brown & burk uk ltd - bromocriptine mesilate - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

meda pharmaceuticals ltd - bromocriptine mesilate - oral tablet - 2.5mg

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - bromocriptine mesilate - tablet - 2.5 milligram(s) - prolactine inhibitors; bromocriptine

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - bromocriptine mesilate - capsule, hard - 5 mg milligram(s) - prolactine inhibitors; bromocriptine

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaniaga manufacturing berhad - bromocriptine mesylate -

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - bromocriptine mesilate 11.48mg equivalent to 10 mg bromocryptine - tablet - 10 mg - active: bromocriptine mesilate 11.48mg equivalent to 10 mg bromocryptine excipient: butylated hydroxyanisole lactose monohydrate magnesium stearate maize starch sodium starch glycolate sunset yellow fcf tragacanth

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bromocriptine mesilate, quantity: 5.735 mg (equivalent: bromocriptine, qty 5 mg) - capsule, hard - excipient ingredients: iron oxide red; gelatin; magnesium stearate; titanium dioxide; lactose monohydrate; shellac; indigo carmine; maleic acid; colloidal anhydrous silica; maize starch - prevention of onset of lactation in the puerperium for clearly defined medical reasons. therapy should be continued for 14 days to prevent rebound lactation. parlodel should not be used to suppress established lactation. treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, parlodel is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated. adjunctive therapy in the management of acromegaly when: (1) the patient refuses surgery and/or radiotherapy; (2) surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months; (3) a manifestation of the acromegaly needs to be brought under con